Max Healthcare Q1 FY27: Profit up 3%, revenue 15% YoY

What Max Healthcare reported for Q1 FY27

Max Healthcare Institute reported a modest rise in profit for the quarter ended June 2026, while revenue and operating profit grew at a faster pace. Net profit increased 3% year-on-year to ₹357 crore, compared with ₹345 crore in the corresponding quarter last year. Revenue from operations rose 15.2% year-on-year to ₹2,835 crore, up from ₹2,460 crore a year earlier. Operating profit also grew in double digits during the quarter, reflecting continued expansion in the company’s operating scale. EBITDA climbed 15% to ₹704 crore from ₹613 crore in the year-ago period. The EBITDA margin remained broadly stable at 24.8%, versus 24.9% in the comparable quarter. The update placed operating performance and margin stability in focus as investors assessed the company’s quarterly trajectory.

Key financial highlights at a glance

The headline numbers showed that growth in revenue and EBITDA tracked each other closely, while profit growth lagged. A stable EBITDA margin suggests operating costs moved broadly in line with revenue during the period. The quarter’s profit expansion, at 3% year-on-year, was slower than the 15% increase in EBITDA, highlighting that below-EBITDA items can influence net profit outcomes. The company’s results were released for the quarter ended June 30, 2026, which it refers to as Q1 FY27. Alongside the Q1 figures, market data and earlier quarterly information circulated in the same results context, giving investors additional reference points. Separately reported company metrics also included net debt for the latest quarter at ₹1,908 crore in a “quick details” snapshot. The company has scheduled an investor and analyst discussion to walk through the numbers and take questions.

Results table: Q1 FY27 vs year-ago quarter

Stock reaction: shares move higher after results

Max Healthcare shares rose after the quarterly results were announced. The stock was trading at ₹1,033 on Thursday afternoon, up 2.5% for the day, as reported alongside the earnings update. Other price snapshots cited around the same period showed the share at about ₹1,017.3 (up 0.97%) and an intraday high of ₹1,021.7 with a low of ₹1,005.9. These different prints reflect timing differences across market updates carried with the results coverage. The immediate market reaction signaled investor attention on revenue growth and steady operating margin. At the same time, the relatively slower net profit growth compared with EBITDA is a key point market participants typically track across quarters.

Board meeting and earnings call schedule

The company will hold a board meeting on August 13, 2026, to consider the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Q1 FY27 results were scheduled to be declared on Thursday, August 13, 2026, as stated in the earnings calendar details carried with the update. Max Healthcare has also scheduled an earnings call for investors and analysts on August 14, 2026. The call is set for 11:00 am IST and will include an interactive question-and-answer session. Senior management is expected to lead the discussion based on the company’s stated plan for the call. For investors, this forum often helps clarify performance drivers and management priorities without relying on market speculation.

Context from the previous quarter and FY26 performance

Alongside the Q1 FY27 coverage, earlier reported consolidated results for Q4 FY26 provided a recent benchmark. Max Healthcare reported Q4 FY26 revenue from operations at ₹2,143 crore versus ₹1,910 crore, an increase of 12% year-on-year. EBITDA in Q4 FY26 was reported at ₹606 crore compared with ₹512 crore, up 19% year-on-year. Profit after tax for Q4 FY26 was ₹342 crore versus ₹319 crore, up 7% year-on-year. For the full FY 2025-26 period, the company reported network gross revenue of ₹10,538 crore (up 16% YoY), operating EBITDA of ₹2,638 crore, and PAT of ₹1,631 crore. The company also reported a final dividend of ₹2 per equity share for FY 2025-26.

Additional data points investors tracked with the update

The results coverage also carried several market and valuation datapoints that investors often use for context. A market capitalisation figure of about ₹98,125.42801916 crore was cited based on the latest share price in the same information set. Valuation ratios were also listed, including a PE ratio of 136.929742356952 and a P/B ratio of 11.1535925586664. Another note in the same update said the stock was trading at 52 times its FY27 earnings estimates. These metrics were presented as part of the surrounding market data and do not change the reported operating numbers, but they shape how the market frames growth and profitability. Separately, EPS (TTM) was cited at 14.82.

Management-related operational cues mentioned earlier

One operational cue referenced in the coverage related to a projected gross top-line benefit discussed in an earlier earnings call. As of the Q4 FY26 earnings call, the company had realised ₹100-110 crore of a projected ₹200 crore gross top-line benefit. Management expected the remaining ₹30-40 crore to start flowing through from Q1 FY27, as per the same note. This is not a reported Q1 FY27 line item by itself, but it is part of the context investors may look for during the earnings call discussion. Such bridge items can influence how analysts reconcile reported revenue growth with operational or contractual drivers.

Market impact and why the quarter mattered

The Q1 FY27 print combined mid-teens revenue growth with a steady EBITDA margin, which is often watched closely in hospital operations where occupancy, case mix, and cost structure can drive swings. EBITDA rising 15% alongside revenue growth of 15.2% indicates operating leverage was not materially diluted, based on the margin staying around 25%. Net profit growth of 3% year-on-year, however, suggests that items below EBITDA affected the translation from operating earnings to bottom line for the quarter. The stock’s move higher on the day of the announcement indicated the market’s focus on the topline expansion and stable margins. Investors will likely use the scheduled August 14 earnings call to seek clarification on profit conversion, net debt positioning of ₹1,908 crore as cited in the quick details snapshot, and the pace of any previously discussed topline benefits.

Conclusion

Max Healthcare’s Q1 FY27 results showed revenue from operations rising to ₹2,835 crore, EBITDA increasing to ₹704 crore, and net profit edging up to ₹357 crore, with margin largely unchanged at 24.8%. Shares traded higher after the announcement, with a reported 2.5% gain to ₹1,033 in Thursday afternoon trade. The company’s board meeting on August 13, 2026 and the earnings call on August 14, 2026 at 11:00 am IST are the next scheduled checkpoints for investors looking for additional management commentary and Q-and-A on the quarter’s drivers.